Rani Therapeutics Holdings Inc
NASDAQ:RANI
Rani Therapeutics Holdings Inc
Rani Therapeutics Holdings, Inc. operates as a clinical stage bio-therapeutics company providing technologies to enable the development of orally administered biologics. The company is headquartered in San Jose, California and currently employs 114 full-time employees. The company went IPO on 2021-07-30. The Company’s technologies enable the development of orally administered biologics. The firm has developed a drug-agnostic oral delivery platform, the RaniPill capsule, which delivers any drug, including molecules, such as peptides, proteins and antibodies. The RaniPill capsule delivers up to a three micrograms (mg) dose of the drug with high bioavailability. Its capsule includes a coating that is designed to withstand stomach acid but dissolves in the jejunum portion of the small intestine. The Company’s product candidate RaniPill capsule is in Phase I clinical trial. The Company’s RaniPill capsule is delivering a variety of biological therapeutics. Its pipeline includes core product candidate programs, such as RT-101, RT-105, RT-102, RT-109 and RT-110. The firm manufactures and assembles RaniPill capsules at its facilities in San Jose and Milpitas, California.
Rani Therapeutics Holdings, Inc. operates as a clinical stage bio-therapeutics company providing technologies to enable the development of orally administered biologics. The company is headquartered in San Jose, California and currently employs 114 full-time employees. The company went IPO on 2021-07-30. The Company’s technologies enable the development of orally administered biologics. The firm has developed a drug-agnostic oral delivery platform, the RaniPill capsule, which delivers any drug, including molecules, such as peptides, proteins and antibodies. The RaniPill capsule delivers up to a three micrograms (mg) dose of the drug with high bioavailability. Its capsule includes a coating that is designed to withstand stomach acid but dissolves in the jejunum portion of the small intestine. The Company’s product candidate RaniPill capsule is in Phase I clinical trial. The Company’s RaniPill capsule is delivering a variety of biological therapeutics. Its pipeline includes core product candidate programs, such as RT-101, RT-105, RT-102, RT-109 and RT-110. The firm manufactures and assembles RaniPill capsules at its facilities in San Jose and Milpitas, California.
Pipeline Focus: Rani is prioritizing its RT-114 oral obesity program, with plans to begin clinical trials in mid-2025, while other programs are on hold due to capital constraints.
Promising Preclinical Data: RT-114 (oral GLP-1/GLP-2) and RT-116 (oral semaglutide) both showed comparable or superior bioavailability and weight loss to subcutaneous injections in animal studies.
Financial Position: Cash and equivalents stood at $27.6 million at year-end 2024, expected to fund operations into Q3 2025.
Cost Controls: R&D and G&A expenses declined significantly year-over-year due to cost containment measures.
Strategic Partnerships: Rani is advancing RT-114 in partnership with ProGen and is open to further partnerships, with ongoing discussions in obesity, immunology, and rare disease.
Manufacturing Updates: $3.7 million impairment taken on certain manufacturing assets; investments made in automation expected to keep cost of goods competitive with injectables.
Guidance: RT-114 Phase 1 is budgeted and expected to start in mid-2025; no further preclinical work required before entering clinic.
